<DOC>
	<DOCNO>NCT00124995</DOCNO>
	<brief_summary>Although widely use treatment pediatric status asthmaticus , intravenous terbutaline potentially significant side effect ; may improve outcome ; may increase Intensive Care Unit ( ICU ) length stay . This study design test efficacy intravenous terbutaline treatment status asthmaticus add intravenous terbutaline placebo standard asthma treatment . The dose terbutaline placebo titrate accord severity illness quantify validated clinical asthma score . Differences outcomes study group , length stay , hospital cost , lung function compare .</brief_summary>
	<brief_title>Trial Terbutaline Treatment Status Asthmaticus Children</brief_title>
	<detailed_description />
	<mesh_term>Status Asthmaticus</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Admission Connecticut Children 's Medical Center ( CCMC ) Pediatric Intensive Care Unit ( PICU ) primary admission diagnosis status asthmaticus Modified Pulmonary Index Score ( MPIS ) great equal 12 Age birth 18 year old Preexisting cardiac pulmonary disease Existing respiratory failure ( require invasive noninvasive mechanical ventilation ) Hemodynamic cardiovascular instability require inotropic support The patient meet one criterion withdrawal study due patient safety concern</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>